

Marcello Dallio

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9170058/marcello-dallio-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

66

papers

1,656

citations

20

h-index

38

g-index

92

ext. papers

2,329

ext. citations

3.9

avg, IF

5.06

L-index

#	Paper	IF	Citations
66	Beneficial Effects of Silybin Treatment After Viral Eradication in Patients With HCV-Related Advanced Chronic Liver Disease: A Pilot Study.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 824879	5.6	
65	PNPLA3, TM6SF2, and MBOAT7 Influence on Nutraceutical Therapy Response for Non-alcoholic Fatty Liver Disease: A Randomized Controlled Trial. <i>Frontiers in Medicine</i> , 2021 , 8, 734847	4.9	4
64	The Role of Resveratrol in Liver Disease: A Comprehensive Review from In Vitro to Clinical Trials. <i>Nutrients</i> , 2021 , 13,	6.7	13
63	The Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights. <i>Nutrients</i> , 2021 , 13,	6.7	11
62	Nutrigenomics and Nutrigenetics in Metabolic- (Dysfunction) Associated Fatty Liver Disease: Novel Insights and Future Perspectives. <i>Nutrients</i> , 2021 , 13,	6.7	4
61	Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort. <i>BMC Infectious Diseases</i> , 2021 , 21, 413	4	1
60	Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology. <i>Journal of Hepatology</i> , 2021 , 75, 1355-1366	13.4	2
59	Risk Factors for Liver Decompensation and HCC in HCV-Cirrhotic Patients after DAAs: A Multicenter Prospective Study. <i>Cancers</i> , 2021 , 13,	6.6	4
58	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. <i>Journal of Hepatology</i> , 2021 , 74, 340-349	13.4	11
57	Dietary Polyphenols and Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2021 , 13,	6.7	24
56	How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma. <i>Cancers</i> , 2021 , 13,	6.6	3
55	Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	13
54	Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis. <i>Metabolomics</i> , 2021 , 17, 12	4.7	16
53	The Bisphenol A Induced Oxidative Stress in Non-Alcoholic Fatty Liver Disease Male Patients: A Clinical Strategy to Antagonize the Progression of the Disease. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 17,	4.6	9
52	Alcohol associated liver disease 2020: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2020 , 52, 374-391	3.3	15
51	Adherence and Effects Derived from FODMAP Diet on Irritable Bowel Syndrome: A Real Life Evaluation of a Large Follow-Up Observation. <i>Nutrients</i> , 2020 , 12,	6.7	12
50	Inflammatory Bowel Diseases: The Role of Gut Microbiota. <i>Current Pharmaceutical Design</i> , 2020 , 26, 2951-29618	3.3	18

49	Light Alcohol Drinking and the Risk of Cancer Development: A Controversial Relationship. <i>Reviews on Recent Clinical Trials</i> , 2020 , 15, 164-177	1.2	3
48	Critical review on the use and abuse of alcohol. When the dose makes the difference. <i>Minerva Medica</i> , 2020 , 111, 344-353	2.2	3
47	Urotensin II receptor expression in patients with ulcerative colitis: a pilot study. <i>Minerva Gastroenterologica E Dietologica</i> , 2020 , 66, 23-28	1.6	1
46	Cirrhosis and frailty assessment in elderly patients: A paradoxical result. <i>Medicine (United States)</i> , 2020 , 99, e18501	1.8	2
45	Extra-Gastric Manifestations of Infection. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	10
44	Non-bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A real-life study. <i>Helicobacter</i> , 2020 , 25, e12694	4.9	8
43	Dimethyl fumarate ameliorates hepatic inflammation in alcohol related liver disease. <i>Liver International</i> , 2020 , 40, 1610-1619	7.9	7
42	Diet and Non-Alcoholic Fatty Liver Disease: The Mediterranean Way. <i>International Journal of Environmental Research and Public Health</i> , 2019 , 16,	4.6	46
41	Chemical Effect of Bisphenol A on Non-Alcoholic Fatty Liver Disease. <i>International Journal of Environmental Research and Public Health</i> , 2019 , 16,	4.6	14
40	NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome. <i>International Journal of Environmental Research and Public Health</i> , 2019 , 16,	4.6	43
39	Silybin-Induced Apoptosis Occurs in Parallel to the Increase of Ceramides Synthesis and miRNAs Secretion in Human Hepatocarcinoma Cells. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	12
38	Ameliorative effect of Silybin on bisphenol A induced oxidative stress, cell proliferation and steroid hormones oxidation in HepG2 cell cultures. <i>Scientific Reports</i> , 2019 , 9, 3228	4.9	20
37	Novel Insights into the Genetic Landscape of Nonalcoholic Fatty Liver Disease. <i>International Journal of Environmental Research and Public Health</i> , 2019 , 16,	4.6	16
36	Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients. <i>Oxidative Medicine and Cellular Longevity</i> , 2019 , 2019, 6742675	6.7	23
35	Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives. <i>International Journal of Environmental Research and Public Health</i> , 2019 , 16,	4.6	12
34	Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data. <i>Pharmacoeconomics</i> , 2019 , 37, 255-266	4.4	8
33	Role of bisphenol A as environmental factor in the promotion of non-alcoholic fatty liver disease: in vitro and clinical study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 826-837	6.1	29
32	Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2018 , 2018, 9547613	6.7	284

31	Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota. <i>Neoplasia</i> , 2018 , 20, 721-733	6.4	47
30	Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis. <i>Antiviral Therapy</i> , 2018 , 23, 129-138	1.6	21
29	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. <i>Lancet, The</i> , 2018 , 391, 2417-2429	4.0	176
28	Vascular Endothelial Dysfunction in Inflammatory Bowel Diseases: Pharmacological and Nonpharmacological Targets. <i>Oxidative Medicine and Cellular Longevity</i> , 2018 , 2018, 2568569	6.7	14
27	Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required?. <i>Digestive and Liver Disease</i> , 2017 , 49, 197-201	3.3	4
26	Human exposure to Bisphenol A and liver health status: Quantification of urinary and circulating levels by LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017 , 140, 105-112	3.5	19
25	Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV. <i>Journal of Hepatology</i> , 2017 ,	13.4	9
24	Mediterranean diet and nonalcoholic fatty liver disease: molecular mechanisms of protection. <i>International Journal of Food Sciences and Nutrition</i> , 2017 , 68, 18-27	3.7	55
23	Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years. <i>Molecules</i> , 2017 , 22,	4.8	179
22	Qualitative and Quantitative Evaluation of Dietary Intake in Patients with Non-Alcoholic Steatohepatitis. <i>Nutrients</i> , 2017 , 9,	6.7	9
21	Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2017 , 26, 261-268	1.4	14
20	Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer. <i>Oncotarget</i> , 2017 , 8, 68305-68316	3.3	20
19	Urotensin-II Receptor: A Double Identity Receptor Involved in Vasoconstriction and in the Development of Digestive Tract Cancers and other Tumors. <i>Current Cancer Drug Targets</i> , 2017 , 17, 109-121	2.8	12
18	A Long-term Treatment with Silybin in Patients with Non-alcoholic Steatohepatitis Stimulates Catalase Activity in Human Endothelial Cells. <i>In Vivo</i> , 2017 , 31, 609-618	2.3	12
17	Gut microbiota and the liver. <i>Minerva Gastroenterology</i> , 2017 , 63, 385-398	3	22
16	Gut microbiota, obesity and metabolic disorders. <i>Minerva Gastroenterology</i> , 2017 , 63, 337-344	3	21
15	Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence. <i>Translational Research</i> , 2016 , 167, 116-24	11	57
14	Alcoholic Liver Disease and Hepatitis C Chronic Infection. <i>Reviews on Recent Clinical Trials</i> , 2016 , 11, 201-2	7.2	5

13	Alcoholic Hepatitis: Pathogenesis, Diagnosis and Treatment. <i>Reviews on Recent Clinical Trials</i> , 2016 , 11, 159-66	1.2	17
12	Epidemiology and Natural History of Alcoholic Liver Disease. <i>Reviews on Recent Clinical Trials</i> , 2016 , 11, 167-74	1.2	39
11	Postoperative Changes in Fecal Bacterial Communities and Fermentation Products in Obese Patients Undergoing Bilio-Intestinal Bypass. <i>Frontiers in Microbiology</i> , 2016 , 7, 200	5.7	67
10	Crohn's disease and skin. <i>United European Gastroenterology Journal</i> , 2016 , 4, 165-71	5.3	5
9	Gastrointestinal Hormones, Intestinal Microbiota and Metabolic Homeostasis in Obese Patients: Effect of Bariatric Surgery. <i>In Vivo</i> , 2016 , 30, 321-30	2.3	38
8	Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis. <i>Oncology Letters</i> , 2015 , 9, 1628-1632	2.6	22
7	Telaprevir may induce adverse cutaneous reactions by a T cell immune-mediated mechanism. <i>Annals of Hepatology</i> , 2015 , 14, 420-424	3.1	6
6	Rapid Virological Response Represents the Highest Prediction Factor of Response to Antiviral Treatment in HCV-Related Chronic Hepatitis: a Multicenter Retrospective Study. <i>Hepatitis Monthly</i> , 2015 , 15, e18640	1.8	6
5	Telaprevir may induce adverse cutaneous reactions by a T cell immune-mediated mechanism. <i>Annals of Hepatology</i> , 2015 , 14, 420-4	3.1	3
4	Silybin-Phosphatidylcholine Complex Protects Human Gastric and Liver Cells from Oxidative Stress. <i>In Vivo</i> , 2015 , 29, 569-75	2.3	17
3	Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 16841-57	5.6	31
2	Skin Adverse Events During Dual and Triple Therapy for HCV-Related Cirrhosis. <i>Hepatitis Monthly</i> , 2014 , 14, e16632	1.8	3
1	Secondary Extramedullary Plasmacytoma of the Duodenum: An Unusual Endoscopic Presentation. <i>Gastroenterology Research</i> , 2013 , 6, 110-111	1.8	1